Capmaxen 200 mg, containing the active ingredient Capmatinib, is a targeted therapy designed for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors carry a MET exon 14 skipping mutation. This mutation leads to abnormal activation of the MET receptor, a key driver of tumor growth and survival. Capmaxen offers a precision medicine approach, selectively inhibiting MET signaling to slow cancer progression and improve outcomes in genetically defined patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Cytotoxic Chemotherapy / Targeted Tyrosine Kinase Inhibitor

Indications

Capmaxen is indicated for adult patients with metastatic NSCLC whose tumors harbor a mutation causing MET exon 14 skipping, as confirmed by an FDA-approved test. This genetic alteration results in a MET receptor missing a regulatory domain, which leads to uncontrolled downstream signaling and tumor proliferation. Capmaxen is specifically designed to target this mutation, providing a personalized treatment option in the management of advanced lung cancer.

Pharmacology

Capmatinib is a selective MET kinase inhibitor that targets both wild-type MET and the exon 14–skipping variant.

• Mechanism of Action: By inhibiting MET receptor phosphorylation, Capmatinib prevents activation of downstream signaling pathways that promote tumor growth and survival.

• Preclinical Studies: Capmatinib demonstrated robust anti-tumor activity in cell lines and mouse xenograft models with MET exon 14 skipping or MET amplification. It effectively blocked MET-dependent proliferation and survival of cancer cells, confirming its potential for clinical use in MET-driven NSCLC.

Dosage & Administration

• Recommended Dose: 200 mg orally twice daily, with or without food, for patients who may require a lower dose due to tolerability or specific clinical considerations.

• Administration Instructions: Swallow tablets whole; do not crush or chew.

• Missed Dose: If a dose is missed or vomited, do not make up the dose; take the next scheduled dose at the usual time.

• Patient Selection: Treatment is only recommended for patients with confirmed MET exon 14 skipping mutations in tumor tissue or plasma specimens.

Interactions

• Capmatinib may interact with other medications metabolized by CYP3A4, potentially affecting drug levels and efficacy.

• Co-administration with strong CYP3A4 inducers or inhibitors should be carefully monitored.

Side Effects

Common adverse effects include:

• Muscle or bone pain

• Fatigue

• Edema

Serious adverse reactions can include interstitial lung disease (ILD)/pneumonitis, elevated liver enzymes, and pancreatitis, requiring close monitoring and possible dose adjustment or discontinuation.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy & Lactation

• Capmatinib may cause fetal harm if administered during pregnancy.

• Breastfeeding should be avoided during treatment and for 1 week after the last dose.

• Both male and female patients of reproductive potential should use effective contraception.

Precautions & Warnings

• Pulmonary toxicity: Permanently discontinue in cases of confirmed ILD/pneumonitis.

• Hepatic monitoring: Regular liver function tests; adjust dose or discontinue if severe elevations occur.

• Pancreatic monitoring: Check amylase and lipase at baseline and periodically.

• Sun exposure: Advise patients to limit direct UV exposure due to photosensitivity risk.

Use in Special Populations

• Safety and efficacy in pediatric patients not established.

• No dosage adjustment required for mild or moderate renal impairment.

• Elderly patients tolerate therapy similarly to younger adults.

Storage Conditions

• Store below 25°C, in a cool, dry place, away from light.

• Keep out of reach of children.